Sun Pharmaceutical Industries Limited (SUNPHARMA,524715), a major Indian pharma company, said on Monday that it has inked a deal to buy Organon & Co.(OGN) for $14 per share in cash with an enterprise value of $11.75 billion.
Kirti Ganorkar, Managing Director of Sun Pharma, said: "This transaction is a logical next step in strengthening Sun Pharma's global business. Together, we will become a partner of choice for acquiring and launching new products. We see strong potential in leveraging Organon's talent pool. In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."
Sun Pharma plans to fund the acquisition, expected to be closed in early 2027, through cash on hand and debt. Post transaction, Sun Pharmaceutical is expected to report a combined revenue of $12.4 billion.
For fiscal 2025, Organon had reported adjusted EBITDA of $1.9 billion, with revenue of $6.2 billion.
SUNPHARMA was up by 7.17% at Rs 1736.60 on the National Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.